Silo Pharma, Mindset Pharma and Terran Biosciences Receive Patents on Psychedelic Treatments and Expand Their IP Portfolios

Silo Pharma Sees Intellectual Property Growth with New U.S. Patent for Novel Ketamine Method for Stress-Induced Affective Disorders

Psychedelics company Silo Pharma Inc. SILO has received a U.S. patent covering claims to the use of the proprietary ketamine drug SPC-15 for the treatment of affective disorders induced by stress, including anxiety and PTSD.

Silo Pharma has an option to license certain assets currently under development by its commercial partner Columbia University, including potential treatments for stress-induced affective disorders and Alzheimer's disease .

SPC-15 is a targeted prophylactic using ketamine compositions as a method of treating and preventing stress-induced affective disorders, working by predicting levels of severity or progression of such disorders and their metabolomic biomarkers. response to treatments.

Mindset Pharma Obtains Third Family 1 Patent and Expands Composition of Matter for Psilocybin Analogs

Next-generation psychedelics company Mindset Pharma Inc. MSSTF has obtained a new US patent for another of its Family 1 applications, this time covering psilocin derivatives for the treatment CNS disorders.

The patent, which includes certain deuterated psilocybin analogs, is the third in Mindset's Family 1 and is the fourth in terms of composition of intellectual property rights for the company.< /p>

See also: This company just created 3 new psychedelics, without the hallucinogenic side effects

Family 1 consists of psilocybin-inspired drug candidates with improved pharmacokinetic (PK), efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement in preclinical studies.

Terran Biosciences publishes international patent applications for DMT, 5-MeO-DMT and MDMA

Private biotech company Terran Biosciences has announced the publication of international PCT patent applications covering novel prodrugs based on DMT, 5-MeO-DMT and MDMA.

These applications are based on preclinical data showing that DMT and 5-MeO-DMT can be made orally active through Terran's proprietary prodrug approach that does not include the traditionally used monoamine oxidase (MAO) inhibitor side effects -nausea, vomiting and changes in blood pressure.

These new compounds are designed as a single oral dose, bypassing first-pass metabolism, then breaking down and releasing high levels of the original active molecule DMT into the brain.

As for the MDMA prodrug, preclinical data shows that it has a significantly longer duration of action than the original psychedelic coupled with a reliable pharmacokinetic profile, which could mean the re-dosing strategy often used in clinical trials of MDMA due to its short-acting effects would no longer be necessary.

Photo: Edited by Benzinga with photo by Blue Planet Studio and ANDREI ASKIRKA on Shutterstock.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.